drugset / Trial / NCT01962545
Optimizing Antithrombotic Care in Patients With AtriaL fibrillatiON and Coronary stEnt (OAC-ALONE) Study
Phase 4
Completed
690 enrolled
Satoshi Shizuta
Daiichi Sankyo · collabResearch Institute for Production Development · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of the study is to evaluate non-inferiority of oral anticoagulant (OAC) monotherapy to OAC plus single antiplatelet therapy (APT) in patients with atrial fibrillation (AF) and prior (\>12 months) coronary stenting.
Timeline
- Start
- 2013-11-05
- Primary completion
- 2017-05-18
- Completion
- 2018-05-18
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Aspirin | Small molecule | 81 mg | — |
| Subject | Aspirin | Small molecule | 324 mg | — |
| Subject | Clopidogrel | Small molecule | 75 mg | — |
| Background | Apixaban | Small molecule | 2.5 mg | Oral |
| Background | Apixaban | Small molecule | 5 mg | Oral |
| Background | Dabigatran | Unknown | 110 mg | Oral |
| Background | Dabigatran | Unknown | 150 mg | Oral |
| Background | Edoxaban | Small molecule | 30 mg | Oral |
| Background | Edoxaban | Small molecule | 60 mg | Oral |
| Background | Rivaroxaban | Other / unclassified | 10 mg | Oral |
| Background | Rivaroxaban | Other / unclassified | 15 mg | Oral |
| Background | Warfarin | Small molecule | — | Oral |